These data confirm that TOR1A disease mutations cause abnormal phosphatidic acid metabolism, and provide a theoretical basis for treating DYT-TOR1A dystonia by inhibiting lipin PAP enzyme activity. This evidence concerns the gene TOR1A and Dystonia.